ArisGlobal Announces Enhanced Global Trial Disclosure and Compliance Solution - Applied Clinical Trials

ADVERTISEMENT

See our 2012 Buyers Guide Digital Edition.
Find Pharma Search Engine
ArisGlobal Announces Enhanced Global Trial Disclosure and Compliance Solution

Source: Company News Release

ArisGlobal, a provider of solutions to the life sciences industry, has announced agDisclosure™ 3.1, a system that enables sponsors to plan, prepare and manage submissions to multiple registries. agDisclosure is the newest addition to ArisGlobal’s Total Clinical™, a comprehensive platform for clinical research that includes EDC, CTMS, ePRO, medical coding, supply chain management and safety reporting -- all accessed via agWorld™, a central clinical portal.

“Clinical trial transparency is an established expectation today and this is being reinforced by regulation in many parts of the world,” commented Mathias Poensgen, product manager at ArisGlobal. “There are many registries and each requires differing data sets with unique business rules based on local regulation. Until standardization is achieved, the entire disclosure process will remain complex. With agDisclosure, sponsors can manage all disclosure activity from a single platform, reusing data sets multiple times while reports, metrics and dashboards give users insight into the worldwide status of their registries.”

agDisclosure is fully 21 CFR Part 11 compliant and provides built-in support for multiple trial registries, including ClinicalTrials.gov and EudraCT. Users can generate and review datasets, run validation checks, and create submission-ready XML files for upload. Key features include:
· Out-of-the-box validation rules.

· Flexible database structure with business rules adaptable to future registry requirements and new fields added without coding efforts.

· Import of data from any CTMS, including ArisGlobal’s agClinical™.


Configurable workflow capabilities support the data review and approval process required for submission while allowing multiple review cycles from different reviewers. Once approved, applicable submission sets can be created with appropriate registry-specific validations applied to ensure the integrity of the submission process. Necessary trial updates can also be submitted to the respective trial registry.

agDisclosure 3.1 is available to customers as a licensed, on-premise solution or as a hosted solution via agOnDemand™, ArisGlobal's highly proven Software-as-a-Service (SaaS) delivery platform.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

Access Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA | July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA | August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA | August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA | August 20-21, 2013
Request Brochure

See All Conferences >>

FindPharma
Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
94%
Borrow lightly from EMA's pathway program?
0%
Create entirely its own pathway program?
6%
View Results
Untitled Document
Source: Company News Release,
Click here